DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

Information source: University of Alabama at Birmingham
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ocular Cicatricial Pemphigoid

Intervention: Rituximab (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: University of Alabama at Birmingham

Official(s) and/or principal investigator(s):
Craig A Elmets, Principal Investigator, Affiliation: University of Alabama at Birmingham

Summary

Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressive agents. These treatments, however, are not successful with all patients. Ritumimab has been very effective in the treatment of other autoimmune disorders, and has recently been shown to be effective for autoimmune blistering pemphigus. We propose that it will also be effective in the treatment of cicatricial pemphigoid.

Clinical Details

Official title: Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks

2. The Proportion of Patients That Experience a Grade 3, Grade 4, or Grade 5 Toxicity Based Reaction on the NCI-CTC System at the Time of Their Infusions and During Follow-up Visits.

Secondary outcome:

1. Stability of Visual Acuity (Snellen's Test) at 16 Weeks

2. Stability of Visual Acuity (Snellen's Test) at 24 Weeks

Detailed description: Cicatricial pemphigoid is an autoimmune blistering disease whcih can affect the skin, mucous membranes, and, in a small subset of patients, the eyes. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments have included high dose systemic steroids, dapsone, and immunosuppressive agents such as azathioprine, methotrexate, cyclophosphamide, and mycophenolate mofetil. However, there are a subgroup of patients who fail to respond to these treatments, develop intolerable side effects, or have contraindications to their use. Patients may also develop resistance to these conventional treatment modalities. For these reasons, alternative treatment modalities are needed. Rituximab has been very effective in the treatment of other autoimmune disorders. It has recently been shown to be effective in the treatment of another autoimmune blistering disorder known as pemphigus. We thus propose that Rituximab will be effective in the treatment of cicatricial pemphigoid.

Eligibility

Minimum age: 19 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Clinical diagnosis of ocular cicatricial pemphigoid (symptoms of conjuctivitis, irritation, burning, increased lacrimation, photophobia, dryness of the eyes along with conjunctival inflammation, trichiasis, and scarring 2. One of the following:

- Failed response to the use of one or more conventional treatments for a minimum

of 10 weeks; or

- Minimal conventional medication doses, with a significant adverse effects,

contradiction to use, or progressive disease despite treatment 3. Adults age 19 and older 4. Adequate renal function as indicated by serum creatinine levels less than 1. 5 Exclusion Criteria: 1. known hypersensitivity to rituximab or its components 2. Age less than 19 years 3. Any other condition deemed by the investigator to be a significant hazard to the subject if the investigational therapy were initiated.

Locations and Contacts

University of Alabama at Birmingham, Birmingham, Alabama 35294, United States
Additional Information

Starting date: January 2006
Last updated: August 5, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017